Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPROSTADIL vs CYTOTEC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular c AMP, and relaxing smooth muscle. It also inhibits platelet aggregation.
Misoprostol is a synthetic prostaglandin E1 analog that binds to prostanoid receptors, leading to inhibition of gastric acid secretion (both basal and stimulated) and increased mucus and bicarbonate secretion, providing mucosal protection. Additionally, it stimulates uterine contractions and cervical ripening.
Treatment of erectile dysfunction (intracavernosal injection or urethral suppository),Palliative therapy to maintain patency of ductus arteriosus in neonates with congenital heart defects pending surgery (intravenous infusion)
Prevention of NSAID-induced gastric ulcers in patients at high risk for complications from a gastric ulcer (e.g., elderly, debilitated, or those with concomitant debilitating disease),Medical termination of pregnancy (in combination with mifepristone or methotrexate),Cervical ripening and induction of labor,Management of postpartum hemorrhage (off-label)
Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.
200 mcg orally four times daily with food for prevention of NSAID-induced gastric ulcers. For termination of pregnancy: 800 mcg vaginally every 12-24 hours or 600 mcg orally as a single dose.
5-10 minutes; rapidly metabolized in the lungs, clinical effect lasts longer due to continuous infusion.
Terminal elimination half-life of misoprostol acid is approximately 20-40 minutes. Due to rapid de-esterification, the half-life of the prodrug is very short (<5 minutes). No accumulation occurs with repeated dosing. In patients with renal impairment, half-life may be prolonged (up to 80 minutes) and dose adjustment may be necessary.
Primarily metabolized via oxidation in the lungs, liver, and kidneys. Approximately 80% inactivated by 15-hydroxy dehydrogenase enzyme on first pass through the lungs.
Misoprostol is rapidly de-esterified to its free acid (misoprostol acid), which is the active metabolite. Further metabolism occurs via beta-oxidation and reduction of the cyclopentane ring. The primary metabolic enzymes are not well-defined, but esterases are involved in the initial hydrolysis.
Primarily via urine (90%) as metabolites; 10% unchanged; minimal fecal excretion.
Following oral administration, misoprostol is rapidly de-esterified to misoprostol acid, the active metabolite. Renal excretion of misoprostol acid is approximately 64-73% of the dose (with 11-17% as unchanged acid) over 24 hours. Fecal excretion accounts for about 15% of the dose, primarily as metabolites. Biliary excretion is minimal. The remainder is eliminated as unidentified metabolites.
80-90% bound to albumin.
Misoprostol acid is approximately 80-90% bound to plasma proteins, primarily albumin. The binding is concentration-independent over therapeutic range.
0.3-0.4 L/kg (large, extensive tissue distribution).
The apparent volume of distribution of misoprostol acid after oral administration is approximately 3-5 L/kg, indicating extensive tissue distribution. The high Vd reflects rapid uptake into tissues such as gastric mucosa, uterus, and kidneys.
IV: 100%; intracavernosal: nearly complete; intra-arterial: high first-pass lung metabolism limits systemic bioavailability.
Oral bioavailability of misoprostol acid is about 70-80% after oral administration due to extensive first-pass metabolism (de-esterification). Vaginal bioavailability is approximately 3 times higher than oral (area under the curve about 3-fold greater) with prolonged absorption. Sublingual and buccal routes also yield higher bioavailability than oral, with sublingual achieving the highest peak concentrations.
No specific GFR-based dose modifications established; use with caution in renal impairment due to potential for hypotension.
No specific dose adjustment recommended for renal impairment based on GFR; use with caution in patients with renal disease due to potential for increased adverse effects.
No specific Child-Pugh based dose modifications established; use with caution in hepatic impairment due to altered metabolism.
No specific dosage adjustment based on Child-Pugh score; however, use with caution in hepatic impairment due to limited data.
For patent ductus arteriosus: initial IV infusion 0.05-0.1 mcg/kg/min; titrate to response; for erectile dysfunction: not typically used in pediatric patients.
Safety and efficacy not established in pediatric patients; no standard weight-based dosing available.
Start at lower end of dosing range (e.g., initial IV bolus 20 mcg) due to increased sensitivity and comorbidity; monitor blood pressure closely.
Dose selection should be cautious, starting at the lower end of the dosing range (e.g., 200 mcg orally twice daily) due to increased sensitivity to gastrointestinal effects and potential for renal impairment in elderly patients.
None.
Cytotec administration by any route is contraindicated in pregnant women because it can cause abortion or harm to the fetus. Cytotec should not be used for labor induction or cervical ripening outside of an approved clinical setting with strict adherence to recommended dosing and route of administration.
Risk of priapism (prolonged erection >4 hours) requiring immediate medical attention,Risk of penile fibrosis or angulation with long-term use,Use with caution in patients with bleeding disorders or on anticoagulants due to bleeding risk,Do not use in neonates with respiratory distress syndrome or persistent fetal circulation,Monitor blood pressure during intravenous use due to hypotension risk
Risk of uterine rupture when used for labor induction, especially in women with prior cesarean section or uterine surgery,May cause diarrhea (dose-dependent), which can be severe and require discontinuation,Hydration status should be monitored due to potential for dehydration from diarrhea,Use caution in patients with inflammatory bowel disease or those at risk for gastrointestinal bleeding
Hypersensitivity to alprostadil,Conditions predisposing to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia),Penile implant or anatomical penis deformity (for erectile dysfunction formulations),Neonates with persistent fetal circulation or respiratory distress syndrome (for intravenous formulation),In women who are pregnant or breastfeeding (not indicated)
Pregnancy (for NSAID ulcer prevention indication),Known hypersensitivity to misoprostol or other prostaglandins,Use for labor induction in patients with uterine scarring (relative contraindication)
No known food interactions. Grapefruit may increase levels via CYP3A4 inhibition, but clinical significance is low for topical/intracavernosal use.
Take with food to decrease incidence of diarrhea, which is dose-related. No specific food restrictions. Avoid alcohol as it may increase GI irritation.
Alprostadil is not indicated for use in pregnancy; systemic exposure poses risk of uterine hyperstimulation and fetal distress. No adequate human studies; animal studies show embryotoxicity. Avoid in pregnancy unless no safer alternative.
Misoprostol (Cytotec) is contraindicated in pregnancy due to its ability to induce uterine contractions and cause fetal harm. First trimester: high risk of fetal death, congenital anomalies (e.g., Moebius sequence), and miscarriage. Second and third trimesters: risk of uterine hyperstimulation, fetal distress, preterm delivery, and fetal demise. Use only for medical termination of pregnancy under strict protocols.
No data on excretion in human milk; M/P ratio unknown. Due to short half-life and local administration, systemic absorption minimal. Use with caution in breastfeeding.
Misoprostol is excreted into breast milk in small amounts (M/P ratio approximately 1.0). No adverse effects reported in breastfed infants with short-term maternal use. However, caution is advised with chronic or high-dose use due to potential for diarrhea in the infant. Generally considered compatible with breastfeeding.
No established dosing in pregnancy; contraindicated in pregnant women. No dose adjustment data available for pregnant populations.
Standard dosing for obstetric indications (e.g., cervical ripening) is lower than for peptic ulcer disease and requires adjustments based on gestational age and clinical response. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may necessitate individualized dosing. For peptic ulcer disease, misoprostol is contraindicated in pregnancy; dose adjustments are not applicable as it should not be used.
Alprostadil causes vasodilation via c AMP increase; watch for hypotension and priapism. For erectile dysfunction, inject into corpus cavernosum, not dorsal vein. For patent ductus arteriosus, monitor respiratory drive as apnea is common in neonates.
Misoprostol (Cytotec) is a prostaglandin E1 analog used for prevention of NSAID-induced gastric ulcers, cervical ripening, and medical abortion. Always confirm pregnancy status before use due to abortifacient properties. For NSAID ulcer prophylaxis, administer 200 mcg four times daily with food; avoid in women of childbearing potential unless NSAID therapy is essential and patient is using effective contraception. For obstetric use, dosing and route differ (oral, vaginal, buccal, sublingual). Monitor for uterine tachysystole, fever, and diarrhea.
Seek immediate medical help if erection lasts more than 4 hours.,Do not use if you have a penile implant or conditions like sickle cell disease.,Avoid driving until you know how this medication affects you.,For injection, rotate injection sites and use within 24hrs of opening vial.,Report any signs of infection at injection site.
Do not take this medication if you are pregnant or plan to become pregnant, as it can cause miscarriage.,Take with food to reduce diarrhea, a common side effect.,Report severe abdominal pain, fever, or heavy vaginal bleeding immediately.,For NSAID ulcer prevention, adherence to dosing schedule is critical.,Store at room temperature away from moisture and heat.
"Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, may reduce the vasodilatory efficacy of alprostadil, a prostaglandin E1 analog. This interaction likely results from pirfenidone-induced downregulation of prostaglandin receptors or modulation of cyclic AMP signaling pathways, leading to diminished smooth muscle relaxation and reduced therapeutic response to alprostadil. Consequently, patients may experience suboptimal vasodilation, potentially compromising treatment for conditions like erectile dysfunction or peripheral arterial disease."
"Concomitant administration of Alprostadil, a vasodilator, and Aminosalicylic acid, a salicylate, may produce additive antiplatelet effects, increasing the risk of bleeding. Alprostadil inhibits platelet aggregation via cAMP elevation, while Aminosalicylic acid inhibits cyclooxygenase, reducing thromboxane A2 synthesis. Clinically, this may result in prolonged bleeding time, easy bruising, or hemorrhage, especially in patients with underlying coagulopathies or those on other anticoagulants."
"Loxoprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins. Alprostadil, a synthetic prostaglandin E1 analog, exerts its therapeutic effects through vasodilation and inhibition of platelet aggregation. The concurrent use of loxoprofen may attenuate the pharmacological activity of alprostadil by diminishing prostaglandin-mediated responses, potentially leading to reduced efficacy in conditions such as erectile dysfunction or peripheral vascular disease."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPROSTADIL vs CYTOTEC, answered by our medical review team.
ALPROSTADIL is a Prostaglandin Analog that works by Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular c AMP, and relaxing smooth muscle. It also inhibits platelet aggregation.. CYTOTEC is a Prostaglandin Analog that works by Misoprostol is a synthetic prostaglandin E1 analog that binds to prostanoid receptors, leading to inhibition of gastric acid secretion (both basal and stimulated) and increased mucus and bicarbonate secretion, providing mucosal protection. Additionally, it stimulates uterine contractions and cervical ripening.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPROSTADIL and CYTOTEC depend on the specific clinical indication. These are both Prostaglandin Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPROSTADIL is: Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.. The standard adult dose of CYTOTEC is: 200 mcg orally four times daily with food for prevention of NSAID-induced gastric ulcers. For termination of pregnancy: 800 mcg vaginally every 12-24 hours or 600 mcg orally as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPROSTADIL and CYTOTEC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPROSTADIL is classified as Category C. Alprostadil is not indicated for use in pregnancy; systemic exposure poses risk of uterine hyperstimulation and fetal distress. No adequate human studies; animal studies show embry. CYTOTEC is classified as Category C. Misoprostol (Cytotec) is contraindicated in pregnancy due to its ability to induce uterine contractions and cause fetal harm. First trimester: high risk of fetal death, congenital . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.